STERIS (STE) Morgan Stanley 22nd Annual Global Healthcare Conference summary

Market trends and procedure volumes

• U.S. healthcare procedure volumes are robust, especially in growth regions like the Sunbelt and Midwest, with high single-digit increases observed.

• Europe is recovering more slowly but has shown consistent positive trends in the past six months, expected to lag the U.S. by six to nine months.

• Elective procedures, such as hip and knee replacements, continue to see strong, sustained demand, driven by lifestyle trends.

Capital equipment and recurring revenue

• Last year's capital equipment sales were exceptionally high due to pent-up demand and prior manufacturing delays, resulting in five quarters' worth of shipments in one year.

• Hospitals are now seeing a path to profitability, with many moving from break-even to cash positive.

• The business has shifted from 50% capital equipment revenue to 80% recurring revenue from consumables and services over the past decade.

• Modest low growth is expected in capital equipment this year, with recurring revenue expected to offset any fluctuations.

Competitive environment and strategy

• The company has consistently gained market share in sterile processing equipment over the past three years.

• Shifts from large inpatient institutions to ambulatory surgery centers require more user-friendly, error-proof equipment.

• Focus remains on maintaining sole source contracts and expanding enterprise solutions rather than aggressive pricing.